Smith & Nephew plc (LON:SN)
London · Delayed Price · Currency is GBP · Price in GBX 1,105.50
-7.50 (-0.67%)
Aug 10, 2026, 4:41 PM GMT
Smith & Nephew Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 6,300 | 6,164 | 5,810 | 5,549 | 5,215 | 5,212 |
Revenue Growth | 2.21% | 6.09% | 4.70% | 6.40% | 0.06% | 14.30% |
Gross Profit Gross Profit Growth | 4,312 | 4,207 | 4,079 | 3,895 | 3,700 | 3,698 |
Operating Income Operating Income Growth | 896 | 877 | 886 | 741 | 658 | 712 |
Net Income Net Income Growth | 635 | 625 | 412 | 263 | 223 | 524 |
Earnings Per Share EPS Growth | 0.74 | 0.72 | 0.47 | 0.30 | 0.26 | 0.60 |
EPS Growth | 2.72% | 52.34% | 56.15% | 18.04% | -57.29% | 16.60% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Knee Implants Knee Implants Growth | 1,002 | 1,011 | 977 | 940 | 899 | 876 |
Hip Implants Hip Implants Growth | 655 | 641 | 619 | 599 | 584 | 612 |
Other Reconstruction Other Reconstruction Growth | 139 | 136 | 101 | 111 | 87 | 92 |
Trauma & Extremities Trauma & Extremities Growth | 661 | 649 | 608 | 564 | 543 | 576 |
Sports Medicine Joint Repair Sports Medicine Joint Repair Growth | 1,131 | 1,067 | 982 | 945 | 870 | 839 |
Arthroscopic Enabling Technologies Arthroscopic Enabling Technologies Growth | 681 | 647 | 632 | 588 | 567 | 590 |
ENT (Ear, Nose and Throat) ENT (Ear, Nose and Throat) Growth | 216 | 220 | 210 | 196 | 153 | 131 |
Advanced Wound Care Advanced Wound Care Growth | 798 | 766 | 735 | 725 | 712 | 731 |
Advanced Wound Bioactives Advanced Wound Bioactives Growth | 600 | 621 | 581 | 553 | 520 | 496 |
Advanced Wound Devices Advanced Wound Devices Growth | 418 | 406 | 365 | 328 | 280 | 269 |
Revenue (Total) Revenue (Total) Growth | 6,300 | 6,164 | 5,810 | 5,549 | 5,215 | 5,212 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 754 | 557 | 619 | 302 | 350 | 1,290 |
Total Debt Total Debt Growth | 3,785 | 3,327 | 3,321 | 3,084 | 2,872 | 3,339 |
Net Cash (Debt) Net Cash Growth | -3,031 | -2,770 | -2,702 | -2,782 | -2,522 | -2,049 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -3.51 | -3.17 | -3.08 | -3.19 | -2.89 | -2.33 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 1,339 | 1,285 | 987 | 608 | 468 | 877 |
Capital Expenditures CapEx Growth | -484 | -433 | -381 | -427 | -358 | -408 |
Free Cash Flow Free Cash Flow Growth | 855 | 852 | 606 | 181 | 110 | 469 |
Free Cash Flow Growth | 0.35% | 40.59% | 234.81% | 64.55% | -76.55% | -4.67% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 68.44% | 68.25% | 70.21% | 70.19% | 70.95% | 70.95% |
Operating Margin | 14.22% | 14.23% | 15.25% | 13.35% | 12.62% | 13.66% |
Pretax Margin | 12.65% | 12.64% | 8.57% | 5.23% | 4.51% | 11.24% |
Profit Margin | 10.08% | 10.14% | 7.09% | 4.74% | 4.28% | 10.05% |
FCF Margin | 13.57% | 13.82% | 10.43% | 3.26% | 2.11% | 9.00% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.290 | 0.391 | 0.375 | 0.375 | 0.375 | 0.375 |
Dividend Per Share Growth | 1.61% | 4.27% | 0% | 0% | 0% | 0% |
Dividend Yield | 2.60% | 2.38% | 3.14% | 2.92% | 3.09% | 2.42% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 19.86 | 22.64 | 26.27 | 45.45 | 52.12 | 29.37 |
Forward PE | 12.93 | 15.14 | 13.18 | 15.24 | 15.96 | 19.09 |
P/FCF Ratio | 14.37 | 16.61 | 17.86 | 66.05 | 105.67 | 32.81 |
PS Ratio | 1.95 | 2.30 | 1.86 | 2.15 | 2.23 | 2.95 |